Healio

Tremfya shows ‘special site’ psoriasis efficacy

Please provide your email address to receive an email when new articles are posted on . Low body surface area psoriasis in sensitive or highly visible areas is often prescribed only topical ...
Morningstar

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...
WFMZ-TV

FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 ...
FiercePharma

Johnson & Johnson sets 'new standard in inclusive marketing' with diverse Tremfya psoriasis ad

Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in clinical studies, commercials, textbooks and beyond. “The research suggests ...
Seeking Alpha

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...
Hosted on MSN

JNJ's Tremfya gets EU approval for pediatric plaque psoriasis

Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and ...